IL6 and familial dilated cardiomyopathy: The analysis proved that the intervention group was significantly better than the control group in reducing IL-6 in DCM patients (MD: −25.92; 95% CI: −31.35 to −20.50; P < 10–6; AMSTAR 10; Evidence class IV; Figure 3).